Prostate
cancer occurs
when cells in prostate glands grow uncontrollably. Prostate is an exocrine
gland that makes the fluid part of semen and lie below the bladder in front of
the rectum. As per the National Institute of Health (NIH), 10.7% of all new
cases of cancer in the U.S. are of prostate cancer.
Access
More About This Research at:
https://www.pharmaproff.com/report/hormone-refractory-prostate-cancer-therapeutics-pipeline-analysis
Moreover,
according to the National Cancer Institute, prostate cancer is the second
leading cause of cancer deaths in men. The symptoms of the disease include
frequent urination, difficulty in holding urine, painful or burning sensation
while urinating, blood in the urine, blood in semen, erectile dysfunction, and
pain in the lower back or pelvis or thighs. The treatment options for prostate
cancer include hormone therapy, chemotherapy and vaccine treatment.
Request
to Get the Sample Pages at:
The drug candidates
of hormone refractory (castration resistant, androgen-independent) prostate
cancer pipeline include, but not limited to, AT-001 and Rucaparib. Some of the
companies having drugs in the hormone refractory (castration resistant,
androgen-independent) prostate cancer pipeline includes GTx Inc., Immunomedics
Inc., and Clovis Oncology Inc.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
